Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of BPC-157 and KPV — mechanism, dosing, side effects, legal status, and pricing.
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH residues 11-13), the smallest alpha-MSH fragment retaining anti-inflammatory activity. Research-only; not FDA-approved. Evidence is primarily preclinical with no controlled human trials.
BPC-157
KPV
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage. Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses commonly used on the grey market.
Key references
All in vivo evidence is preclinical. Dalmasso et al. (Gastroenterology 2008) demonstrated PepT1-mediated uptake and reduction of DSS/TNBS colitis in mice. Kannengiesser et al. (Inflammatory Bowel Diseases 2008) showed anti-inflammatory effects in two murine colitis models. Additional preclinical work (largely from the Merlin group at Georgia State) explores nanoparticle/conjugate oral delivery for IBD, and models of atopic dermatitis, asthma, and wound healing show activity. No controlled human trials have been published.
Key references
BPC-157 (Recovery) and KPV (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs